EPP3: Investment in Sterile Injectables/Infusions by Kotra Pharma

Kotra Pharma will be investing RM60 million to develop a manufacturing line to produce sterile injectable or infusion products. These products are currently not produced in Malaysia and it will be a pioneering initiative.
  • Investment by 2020 (million)
  • GNI Impact by 2020 (million)
  • Jobs created by 2020
The manufacturing line will be an addition to the world class pharmaceutical plant worth RM152 million which was initiated in 2010.

Kotra will be able to supply the Ministry of Health through this investment which will then substitute the need to import these products. Kotra currently exports to over 40 countries to date and is looking to expand the product range in its export market.

Source: ETP website

Post a Comment